tamsulosin

hydrochloride

CLINICAL USE

Treatment of benign prostatic hyperplasia

DOSE IN NORMAL RENAL FUNCTION

400 mcg in the morning after breakfast

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :445

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :99

%Excreted unchanged in urine &nbsp &nbsp : 9

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.2

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :4–5.5 (M/R: 10–15)/Increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Use with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR 10 to 20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Antidepressants: enhanced hypotensive effect with MAOIs

Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect

Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect

Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect

Moxisylyte: possibly severe postural hypotension

Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect, avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Swallow whole with 150 mL of water while sitting or standingProtein binding is increased in renal impairment

Tags: post-by-auto-php